Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 291831 | 3.72 |
09:34 ET | 194625 | 3.6245 |
09:36 ET | 157855 | 3.746 |
09:38 ET | 174440 | 3.785 |
09:39 ET | 147499 | 3.725 |
09:41 ET | 209504 | 3.721 |
09:43 ET | 96832 | 3.715 |
09:45 ET | 94789 | 3.6699 |
09:48 ET | 93726 | 3.68 |
09:50 ET | 118716 | 3.73 |
09:52 ET | 169614 | 3.7301 |
09:54 ET | 46710 | 3.732 |
09:56 ET | 151405 | 3.8933 |
09:57 ET | 174426 | 3.83 |
09:59 ET | 85130 | 3.83 |
10:01 ET | 74763 | 3.88 |
10:03 ET | 237141 | 3.885 |
10:06 ET | 213638 | 3.9686 |
10:08 ET | 154489 | 3.999 |
10:10 ET | 159276 | 3.92 |
10:12 ET | 125288 | 3.9024 |
10:14 ET | 55380 | 3.865 |
10:15 ET | 80004 | 3.9113 |
10:17 ET | 95778 | 3.85 |
10:19 ET | 26164 | 3.88 |
10:21 ET | 59013 | 3.9201 |
10:24 ET | 72819 | 3.9414 |
10:26 ET | 106781 | 3.965 |
10:28 ET | 68689 | 3.905 |
10:30 ET | 9843 | 3.9 |
10:32 ET | 89778 | 3.9705 |
10:33 ET | 96719 | 4 |
10:35 ET | 77825 | 4.07 |
10:37 ET | 129031 | 4.181 |
10:39 ET | 78063 | 4.15 |
10:42 ET | 48285 | 4.1 |
10:44 ET | 134481 | 4.27 |
10:46 ET | 131184 | 4.2791 |
10:48 ET | 113868 | 4.205 |
10:50 ET | 100952 | 4.15 |
10:51 ET | 58859 | 4.1309 |
10:53 ET | 61873 | 4.1701 |
10:55 ET | 64245 | 4.205 |
10:57 ET | 51461 | 4.22 |
11:00 ET | 56547 | 4.29 |
11:02 ET | 80785 | 4.25 |
11:04 ET | 53388 | 4.22 |
11:06 ET | 23961 | 4.2 |
11:08 ET | 8115 | 4.205 |
11:09 ET | 89565 | 4.201 |
11:11 ET | 62439 | 4.17 |
11:13 ET | 33729 | 4.165 |
11:15 ET | 32902 | 4.1599 |
11:18 ET | 28398 | 4.19 |
11:20 ET | 11001 | 4.175 |
11:22 ET | 12189 | 4.187 |
11:24 ET | 36417 | 4.19 |
11:26 ET | 36748 | 4.15 |
11:27 ET | 17319 | 4.15 |
11:29 ET | 41581 | 4.1527 |
11:31 ET | 58547 | 4.19 |
11:33 ET | 25770 | 4.17 |
11:36 ET | 31506 | 4.21 |
11:38 ET | 20736 | 4.23 |
11:40 ET | 55676 | 4.18 |
11:42 ET | 28567 | 4.21 |
11:44 ET | 60136 | 4.24 |
11:45 ET | 49828 | 4.26 |
11:47 ET | 38193 | 4.27 |
11:49 ET | 23886 | 4.2901 |
11:51 ET | 23095 | 4.255 |
11:54 ET | 49145 | 4.2501 |
11:56 ET | 3462 | 4.2512 |
11:58 ET | 9652 | 4.26 |
12:00 ET | 59528 | 4.2 |
12:02 ET | 17598 | 4.225 |
12:03 ET | 34897 | 4.28 |
12:05 ET | 18156 | 4.28 |
12:07 ET | 14643 | 4.2797 |
12:09 ET | 44026 | 4.24 |
12:12 ET | 36490 | 4.21 |
12:14 ET | 57704 | 4.15 |
12:16 ET | 22408 | 4.18 |
12:18 ET | 20781 | 4.1994 |
12:20 ET | 8188 | 4.18 |
12:21 ET | 28693 | 4.19 |
12:23 ET | 19587 | 4.1688 |
12:25 ET | 35283 | 4.15 |
12:27 ET | 20064 | 4.15 |
12:30 ET | 11043 | 4.15 |
12:32 ET | 27000 | 4.1685 |
12:34 ET | 7127 | 4.15 |
12:36 ET | 41818 | 4.155 |
12:38 ET | 19683 | 4.16 |
12:39 ET | 17257 | 4.1523 |
12:41 ET | 1973 | 4.15 |
12:43 ET | 23895 | 4.155 |
12:45 ET | 10626 | 4.15 |
12:48 ET | 151456 | 4.0315 |
12:50 ET | 87857 | 4.02 |
12:52 ET | 25850 | 4.0005 |
12:54 ET | 11563 | 4.001 |
12:56 ET | 9858 | 4.0199 |
12:57 ET | 33181 | 4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 378.1M | -1.1x | --- |
enGene Holdings Inc | 387.6M | -1.8x | --- |
Terns Pharmaceuticals Inc | 388.7M | -5.9x | --- |
LENZ Therapeutics Inc | 390.4M | -1.0x | --- |
Aura Biosciences Inc | 364.1M | -4.1x | --- |
Fibrobiologics Inc | 398.5M | -8.8x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $378.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.